Cancer risk in families
If you have family members with cancer, you may wonder if you are at risk of developing it too (if it “runs in the family”). Sometimes a gene mutation that can cause cancer is passed on to you by your parents (inherited). Cancers caused by inherited gene mutations are called inherited cancers. And sometimes cancer […]
About Glioblastoma (GBM)
Overview Tumour Group: Gliomas WHO Grade: Grade IV Prevalence/Incidence: The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours. GBMs increase in frequency with age, and affect […]
Lung Cancer Screening in Real World Has High False-Positive Rate
By Kelly YoungEdited by: David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD A pair of studies in JAMA Internal Medicine illustrate the difficulties of implementing lung cancer screening. In the first, eight Veterans Health Administration medical centers identified and screened patients using low-dose computed tomography (LDCT). Over 2100 patients who were eligible for screening based […]
Opportunities and challenges for lung cancer screening in China
Chuanli Ren, Chongxu Han Abstract China accounts for nearly half of the incidence and mortality of lung cancer in the world. Furthermore, trends in lung cancer in China are increasing younger in age and the situation is deteriorating. As a whole although screening for early lung cancer may cause a small fraction of overdiagnosis and anxiety of […]
BioMark Contributes Additional Scientific Publication
Vancouver, British Columbia – (March 14th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal Future Science OA. […]
BioMark Announces New Patent Granted in China
Vancouver, British Columbia – (March 12, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been granted in China on February 15, 2019. Rashid Ahmed, President and CEO, says, “Granting of this patent expands […]
Dr. Myron Weisfedlt Joins BioMark’s Scientific Advisory Team
Vancouver, British Columbia – (November 5th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that Dr. Myron Weisfeldt will be joining BioMark’s Scientific Advisory Team. Mr. Rashid Ahmed, CEO and President of BioMark Diagnostics says: “We are extremely proud and honored to have Dr. Myron Weisfeldt […]
BioMark Closes Final Tranche of Private Placement Offering
October 4th, 2018 – Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of September 20, 2017, it has closed the final tranche of a non-brokered private placement for gross proceeds of $222,100.00 wherein BioMark issued 2,221,000 […]
Dr. Sandeep Singhal Joins BioMaark Scientific Advisory Team
Vancouver, British Columbia – (October 2nd, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Sandeep Singhal to its scientific advisory team. Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Singhal into our scientific advisory team. He provides expertise […]
BioMark Contributes in Scientific Publication
Vancouver, British Columbia – (September 26, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer has been published in the peer-reviewed journal Future Science OA. Rashid Ahmed, President and CEO, says, “We are extremely excited […]
